These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11937593)

  • 21. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective.
    Meta J; Seltzer M; Schiepers C; Silverman DH; Ariannejad M; Gambhir SS; Phelps ME; Valk P; Czernin J
    J Nucl Med; 2001 Apr; 42(4):586-90. PubMed ID: 11337546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer.
    Simó M; Lomeña F; Setoain J; Pérez G; Castellucci P; Costansa JM; Setoain-Quinquer J; Doménech-Torné F; Carrió I
    Nucl Med Commun; 2002 Oct; 23(10):975-82. PubMed ID: 12352596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET and PET-CT for evaluation of colorectal carcinoma.
    Delbeke D; Martin WH
    Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.
    Eubank WB; Mankoff D; Bhattacharya M; Gralow J; Linden H; Ellis G; Lindsley S; Austin-Seymour M; Livingston R
    AJR Am J Roentgenol; 2004 Aug; 183(2):479-86. PubMed ID: 15269044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR; Martin WH; Delbeke D
    Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
    Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
    Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
    Israel O; Mor M; Guralnik L; Hermoni N; Gaitini D; Bar-Shalom R; Keidar Z; Epelbaum R
    J Nucl Med; 2004 Dec; 45(12):2045-51. PubMed ID: 15585480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitfalls and mimickers on (18)F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: An analysis from 37 patients.
    Audollent R; Eveno C; Dohan A; Sarda L; Jouvin I; Soyer P; Pocard M
    J Visc Surg; 2015 Nov; 152(5):285-91. PubMed ID: 26115889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
    Kim JH; Czernin J; Allen-Auerbach MS; Halpern BS; Fueger BJ; Hecht JR; Ratib O; Phelps ME; Weber WA
    J Nucl Med; 2005 Apr; 46(4):587-95. PubMed ID: 15809480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.